WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease

Pharmacology, Toxicology and Pharmaceutical Science

• 1,2,3,6 Tetrahydro 1 Methyl 4 Phenylpyridine 100%
• Parkinson Disease 40%
• Cannabinoid 2 Receptor 30%
• Dopamine 20%
• Cannabinoid Receptor Agonist 20%
• Mouse 20%
• Receptor 10%
• Toxicity 10%
• Disease Exacerbation 10%
• Tyrosine 3 Monooxygenase 10%
• Neurotoxicity 10%
• Neuroprotective Agent 10%
• Mouse Model 10%
• Cannabinoid 1 Receptor 10%
• Cognitive Defect 10%
• 3,4 Dihydroxyphenylacetic Acid 10%
• Cannabinoid 2 Receptor Agonist 10%
• Nervous System Inflammation 10%
• Motor Dysfunction 10%
• Symptom 10%
• Pharmacotherapy 10%
• Striatonigral Degeneration 10%
• 2 Methyl 3 (1 Naphthoyl) 1 Propylindole 10%

Neuroscience

• Tetrahydropyridine 100%
• Parkinson's Disease 40%
• Cannabinoid 2 Receptor 30%
• Neuron 30%
• Dopamine 20%
• Receptor Agonists 20%
• Substantia Nigra Pars Compacta 20%
• Eicosanoid Receptor 10%
• Neuroprotective Agent 10%
• Tyrosine Hydroxylase 10%
• Cognitive Disorders 10%
• Cannabinoid 1 Receptor 10%
• Dorsal Striatum 10%
• Cell Loss 10%
• CB2 Receptor Agonist 10%
• Midbrain 10%
• Neurotoxicity 10%